Cells · 2022 · 25 citations · 45 references
Veterinary MedicineCell BiologyPathobiologyCell TherapyCell Therapy TranslationInflammationLipid MetabolismLiver DiseaseMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyMetabolic InflammationMetabolic Liver DiseaseBone Marrow - Derived CellsBone Marrow-derived Mesenchymal Stromal CellsHepatic Lipid AccumulationHepatic Lipid MetabolismHepatic Lipid StorageHigh-fat Diet-induced Liver InjuryLipid Storage RegulationTransplantation
Mesenchymal stromal cells (MSC) increasingly emerge as an option to ameliorate non-alcoholic steatohepatitis (NASH), a serious disease, which untreated may progress to liver cirrhosis and cancer. Before clinical translation, the mode of action of MSC needs to be established. Here, we established NASH in an immune-deficient mouse model by feeding a high fat diet. Human bone-marrow-derived MSC were delivered to the liver via intrasplenic transplantation. As verified by biochemical and image analyses, human mesenchymal stromal cells improved high-fat-diet-induced NASH in the mouse liver by decreasing hepatic lipid content and inflammation, as well as by restoring tissue homeostasis. MSC-mediated changes in gene expression indicated the switch from lipid storage to lipid utilization. It was obvious that host mouse hepatocytes harbored human mitochondria. Thus, it is feasible that resolution of NASH in mouse livers involved the donation of human mitochondria to the mouse hepatocytes. Therefore, human MSC might provide oxidative capacity for lipid breakdown followed by restoration of metabolic and tissue homeostasis.
45
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations